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Atrial fibrillation (AF) is a common heart
rhythm disorder that causes the upper chamber of
the heart to quiver rather than squeeze blood out
with each beat. When blood is allowed to pool in the
atrium, it can form clots [1]. Anticoagulation with
warfarin has been proven effective for the preven-
tion of clot-related strokes in AF. But it is used con-
servatively, largely because it can cause serious
bleeding in some patients [2]. It also necessitates
regular blood tests and may require that patients
restrict certain physical activities.  The Stroke Pre-
vention in Atrial Fibrillation (SPAF) studies have
documented the benefits of chronic warfarin thera-
py in reducing the risk of stroke [3].
The prevention of strokes has traditionally
been plagued by the tedious task of continuously
adjusting anti-coagulation medicines. The emer-
gence of a new device called Watchman® promises
to mechanically prevent the formation of dangerous
emboli, by occluding left atrial appendage, a place
where most thrombi form in patients with AF [4].
The left atrial appendage (LAA) has been iden-
tified as a major source of thrombi in patients with
AF. Ligation of the LAA surgically has been done
for many years. Though this is a very invasive tech-
nique, limited data appears to demonstrate a bene-
fit in patients at risk of AF related strokes. Recent-
ly, a transcatheter approach to isolate the LAA has
been developed [5].
The Watchman® LAA system [6] is made of
nitinol (a self expanding metal) with the atrial fac-
ing surface covered with a thin permeable polyes-
ter material. The device is constrained within
a catheter until delivery into the LAA and is avail-
able in multiple sizes to accommodate the unique
anatomy of each patient (Fig. 1).
The idea behind the Watchman is simply to
block the opening of the troublesome appendage
with a mesh, squid-resembling stent so that the clots
that do form cannot escape and cause trouble else-
where [7]. To implant the Watchman®, an interven-
tional cardiologist guides the device into the heart
through a catheter inserted in a vein in the upper
leg [8, 9]. The catheter is threaded first into the
right atrium, then into the left atrium through
a puncture in the wall separating the two upper cham-
bers of the heart. Once the catheter is positioned in
the opening of LAA, the Watchman® is released
and left permanently in place to block the forma-
tion and release of blood clots. An animation illus-
trating Watchman’s principle of operation can be
found at this URL: http://www.atritech.net/media/
/deviceanimation.aspx (Fig. 2).
Clinical trials of the device, however, had until
now been small scale (there was a pilot study
with about 30 people in 2007) [6]. The new larger
Embolic Protection in Patients with Atrial Fibrillation
(PROTECT-AF) study was designed to demon-
strate the safety and efficacy of the Watchman® de-
vice in patients with non-valvular AF who require
treatment for potential thrombus formation, are
eligible for warfarin therapy and who have at least
one of the following risk factors: congestive heart
failure, hypertension, age 75+ years, diabetes mel-
litus and/or prior stroke or transient ischemic at-
tack. The results of this study just announced at the
58th Scientific Session of the American College of
Cardiology indicate that the device indeed has
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Figure 1. The delivery and placement of the Watchman
in the left atrium.
great promise as an alternative to anticoagulant
therapy [10].
In the PROTECT-AF trial [11], researchers
compared the current standard therapy (anticoag-
ulation with warfarin) to a fabric-covered expanda-
ble nitinol cage known as Watchman, which blocks
blood clots that typically form in the LAA, an out-
pouching of the left atrium. They found that the
Watchman reduced by some 30% the combined risk
of cardiovascular death and stroke, both ischemic (the
type caused by a blood clot) and hemorrhagic (the type
caused by excessive bleeding into the brain).
The trial’s principal investigator, David R.
Holmes, Jr., MD, Scripps Professor of Medicine at
the Mayo Graduate School of Medicine, Rochester,
MN, USA, stated that patients with AF have a six-
fold increased risk of stroke and therefore require
long-term anticoagulation therapy. The placement
of this device results in excellent long-term out-
comes: effective ischemic stroke prevention with the
elimination of hemorrhagic strokes and major bleed-
ing often associated with the use of warfarin [12].
To implant the Watchman, an interventional
cardiologist guides the device into the heart through
a catheter inserted in a vein in the upper leg. The
catheter is threaded first into the right atrium, then
into the left atrium through a puncture in the wall
separating the two upper chambers of the heart.
Once the catheter is positioned in the opening of
the LAA, the Watchman is released and left perma-
nently in place to block the formation and release
of blood clots.
For the PROTECT-AF study, 707 patients with
non-valvular AF were randomly assigned to closure
of the LAA with the Watchman device (463 patients)
followed by discontinuation of warfarin, or to long-
term treatment with warfarin (244 patients). Of
those who got the Watchman, there were 15 strokes
and 17 deaths. Of those who didn’t and were treat-
ed with coumadin, there were 11 strokes and
15 deaths. This amounts to an approximate 3% risk
of clot-related problems with the device, and 5%
without. The study found, in more than 900 patient-
-years of follow-up, that the combined rate of stroke
(ischemic and hemorrhagic) and cardiovascular
death, the primary measures of effectiveness, was
3.4 per 100 patient-years in the device group vs.
5.0 per 100 patient-years in the warfarin group. This
was a reduction of 32% (relative risk [RR], 0.68).
As for the safety of the device, the researchers ob-
served more procedure-related complications in
patients treated with the device (8.7 vs. 4.2 per
100 patient-years; RR 2.08). Most complications
were related to device implantation. However, af-
ter successful implantation of the Watchman and
discontinuation of warfarin therapy, complication
rates were significantly lower with device therapy
(1.7 vs. 4.2 per 100 patient-years; RR 0.40).
While the Watchman’s overall advantage met
noninferiority criteria [13], the 91% reduction in the
hemorrhagic stroke rate (0.2% vs. 1.9%) met supe-
riority criteria. However, these benefits in the ran-
domized PROTECT-AF trial came at the price of
a doubled risk of complications, predominantly early
Figure 2. Watchman left atrial appendage (LAA) closure
device in situ.
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pericardial effusion. Therefore, there may be a great-
er up-front risk from the Watchman procedure, but
90% of patients with the device were able to stop
coumadin completely, and the device appears to func-
tion at least as well as the medication (Table 1).
The primary efficacy end-point included all
strokes, including ischemic and hemorrhagic, car-
diovascular or unexplained death, and systemic em-
bolization.
Results on primary efficacy were “just the re-
verse” of the safety end-point, Dr Holmes told the
American College of Cardiology. “The patients who
received the Watchman device had primary effica-
cy rates that were improved, and noninferiority cri-
teria were met,” he added, with a relative risk re-
duction of 32% (Table 2).
Some of the efficacy stroke events were also
counted as safety events. There were five periproce-
dural ischemic strokes, three of which were related
to air embolization during the procedure. There were
six hemorrhagic strokes in the control group and one
in the device group, a stroke that occurred 15 days
after the procedure, when the patient was still being
treated with warfarin. Of six patients in the control
group who had a hemorrhagic stroke, four died.
For all strokes, event-free probability was im-
proved and noninferiority criteria met, he noted.
Ischemic strokes were higher in the device group,
14 events vs. five events on warfarin, but hemor-
rhagic stroke was lower in the device group, meet-
ing superiority criteria (Table 3).
They found a time effect in the frequency of
pericardial effusion; although serious effusion oc-
curred in 5.0% overall, it fell from 6.5% in early
patients to 4.4% in later patients.
The researchers concluded that the Watchman
is an effective alternative to warfarin therapy for
preventing stroke in patients with AF. The device
has the potential to completely replace blood thin-
ning drugs and bring relief to the patients with AF.
There were some dislodgements during the
trial. Two occurred in the pilot phase before im-
provements in design. Another occurred during the
main phase of the trial, several months after place-
ment. In that case, the patient was asymptomatic,
and researchers discovered the device missing ser-
endipitously during echocardiography. They later
retrieved it from the abdomen. The dislodgement
rate was estimated to be one in 350 or 400.
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Table 1. PROTECT-AF: Primary safety results.
End point Device events Device rate Control events Control rate Relative risk
(n)  (95% CI)  (n)  (95% CI)  (95% CI)
Primary safety results 48 8.7 13 4.2 2.08
(900 patient-year cohort) (6.4–11.3) (2.2–6.7) (1.18–4.13)
CI — confidence interval
Table 2. PROTECT-AF: Primary efficacy results.
End point Device events Device rate Control events Control rate Relative risk
(n)  (95% CI)  (n)  (95% CI)  (95% CI)
Primary efficacy results 20 3.4 16 5.0 0.68
(900 patient-year cohort) (2.1–5.2) (2.8–7.6) (0.37–1.41)
CI — confidence interval
Table 3. PROTECT-AF: All stroke, hemorrhagic stroke and ischemic stroke by intervention.
End point Device event rate (95% CI) Control event rate (95% CI) Relative risk (95% CI)
All stroke 2.6 (1.5–4.1) 3.5 (1.7–5.7) 0.74 (0.36–1.76)
Ischemic stroke 2.4 (1.3–3.9) 1.6 (0.5–3.1) 1.53 (0.654–5.43)
Hemorrhagic stroke 0.2 (0.0–0.6) 1.9 (0.7–3.7) 0.09 (0.00–0.45)
CI — confidence interval
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